BPC-157 vs Substance P Antagonists
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
NK1 receptor blockers that reduce pain signals and nausea at the source
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
BPC-157
250–500 mcg
Substance P Antagonists
150–150 mg
Frequency
BPC-157
Once daily
Substance P Antagonists
Once daily
Administration
BPC-157
Subcutaneous injection
Substance P Antagonists
Oral capsule
Cycle length
BPC-157
4-6 weeks
Substance P Antagonists
Ongoing/indefinite
Onset speed
BPC-157
Moderate (1-2 weeks)
Substance P Antagonists
Moderate (1-2 weeks)
Evidence level
BPC-157
Strong preclinical (extensive animal studies)
Substance P Antagonists
Moderate human trials (Phase 1-2)
Benefit ratings
Primary Benefit
Secondary Benefit
Additional Benefit
Anti-Nausea & Antiemetic
Pain Modulation
Neuroprotection
Compound specifications
BPC-157
Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0
Substance P Antagonists
Molecular formula
C23H21F7N4O3
Molecular weight
534.4 g/mol
Half-life
9-13 hours (elimination half-life)
Bioavailability
Approximately 60-65% oral bioavailability; food may increase absorption
CAS number
170729-80-3
Dosing compared
BPC-157
Subcutaneous
250 mcg
Once daily · 1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily · 4-6 weeks
Commonly used range for tissue and tendon recovery in research practice [1][3].
500 mcg
Twice daily · 6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Substance P Antagonists
Intravenous
150 mg (fosaprepitant)
Single dose, 30 min before chemotherapy on day 1 · One dose per chemotherapy cycle
FDA-approved single-dose IV prodrug regimen, with a 5-HT3 antagonist and corticosteroid [5].
Oral
125 mg on day 1, then 80 mg on days 2-3 (aprepitant)
Once daily · 3-day course per chemotherapy cycle
FDA-approved oral regimen: 125 mg 1 hour before chemotherapy, then 80 mg each morning on days 2 and 3 [5].
Best suited for
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]
Substance P Antagonists
Managing severe nausea from cancer treatments
Substance P Antagonists is particularly well-suited for individuals focused on managing severe nausea from cancer treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic pain reduction
Substance P Antagonists is particularly well-suited for individuals focused on chronic pain reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving quality of life during intensive medical therapy
Substance P Antagonists is particularly well-suited for individuals focused on improving quality of life during intensive medical therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Substance P Antagonists
Common
- Headache
- Fatigue or weakness
- Constipation
Uncommon
- Loss of appetite
- Dizziness
Serious
- Stevens-Johnson Syndrome (SJS)
Safety & evidence
BPC-157
Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- Pregnancy
- Breastfeeding
- Active cancer
- History of cancer
Substance P Antagonists
Evidence level
Moderate human trials (Phase 1-2)
FDA status
FDA approved for this use
Safety overview
Aprepitant (the primary NK1 antagonist) has been FDA-approved since 2003 with extensive safety data in over 50,000 cancer patients receiving highly emetogenic chemotherapy. Most common adverse events are mild to moderate—headache (15-20%), fatigue, and constipation—which are often difficult to attribute solely to aprepitant versus underlying malignancy or chemotherapy effects. Serious but rare adverse events include Stevens-Johnson syndrome (extremely uncommon) and QT prolongation (in susceptible individuals), requiring baseline ECG evaluation in high-risk patients.
Contraindications
- Severe hypersensitivity to aprepitant or any component
- Concurrent use with certain other medications that affect the liver
- Severe cardiac conditions
Which is right for you?
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health
Choose Substance P Antagonists if...
- Managing severe nausea from cancer treatments
- Chronic pain reduction
- Improving quality of life during intensive medical therapy